GRAIL faces class action over NHS-Galleri trial after 50.55% stock drop

The lawsuit, filed in the Northern District of California, centers on statements about the cancer screening trial after GRAIL disclosed it did not meet its primary endpoint.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.